运脾强生方提高腹膜透析患者生存质量的疗效观察

江燕; 盛梅笑; 宋欢; 袁晓玲; 殷玲

运脾强生方提高腹膜透析患者生存质量的疗效观察

1.
南京中医药大学附属医院，江苏南京 210029
2.
南京中医药大学第一临床医学院，江苏南京 210023

计量
- 文章访问数: 645
- HTML全文浏览量: 3
- PDF下载量: 606
- 被引次数: 0
出版历程
- 收稿日期: 2013-06-20
- 修回日期: 2013-08-01
- 刊出日期: 2013-11-10

Effect of Yunpiqiangsheng Fang on Improving Life Quality of Peritoneal Dialysis Patients

1.
The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China
2.
The First Medical College, Nanjing University of Chinese Medicine, 210023, China

摘要

摘要: 目的观察运脾强生方对腹膜透析（PD）患者生存质量（QOL）的影响。方法共55例患者随机分为2组，治疗组26例，对照组29例。在西医基础治疗与常规PD治疗的前提下，治疗组加用运脾强生方，疗程3个月。观察治疗后KDQOL-SF^TM1.3量表评分、营养指标（Hb、Alb、pre-A、TSF、MAC、MAMC、MQSGA）、代谢指标（TC、TG、Ca²⁺、P³⁺、PTH）及透析相关指标（BUN、Scr、KT/V、Ccr）的变化。结果 ①治疗组能够改善KDQOL-SF^TM1.3量表总体评分，总有效率为83.3%，优于对照组（P<0.01），尤其在改善患者症状与一般健康状况、改善睡眠、减轻肾病对生活的影响、增强体力方面（P<0.05）。② 治疗组治疗后MQSGA与治疗前比较明显下降（P<0.01），Hb、Alb、pre-A、TSF上升（P<0.05），其中MQSGA、Hb、pre-A、TSF的变化优于对照组（P<0.05）。③2组TC、TG、Ca²⁺、P³⁺、PTH组内与组间比较无统计学意义（P>0.05）。④ 治疗组治疗后BUN较治疗前下降（P<0.05），其下降幅度优于对照组（P<0.05），2组Scr、KT/V、Ccr组内与组间比较无统计学意义（P>0.05）。结论运脾强生方有助于提高PD患者的QOL，其作用与该方能够增进食欲，增强胃肠消化吸收能力，调节脏腑整体功能，进而改善患者的营养状况有关。
- 运脾强生方 /
- 腹膜透析 /
- 生存质量 /
- 临床研究
Abstract: OBJECTIVE To observe the effect of Yunpiqiangsheng Fang on improving quality of life (QOL) of peritoneal dialysis (PD) patients. METHODS 55 patients were divided into treatment group (26) and control group (29). Control group received western medicine and conventional PD treatment apart from which treatment group was added Yunpiqiangsheng Fang as well for three months. After the treatment， changes in KDQOL-SFTM1.3 scale score， nutrition indicators (Hb， Alb， pre-A， TSF， MAC， MAMC， MQSGA)， metabolic parameters (TC， TG， Ca²⁺， P³⁺， PTH) and dialysis-related indicators (BUN， Scr， KT / V， Ccr) were observed. RESULTS ① Treatment group can increase KDQOL-SFTM1.3 scale score with total effective rate 83.3 %， superior to control group (P<0.01) especially in improving the symptoms， health condition and sleep， relieving the impact of kidney disease for life， and enhancing strengh(P<0.05). ② After treatment， MQSGA in treatment group significantly decreased (P<0.01) while Hb， Alb， pre-A， TSF increased (P<0.05) compared with that before treatment. The changes of MQSGA， Hb， pre-A， TSF are better than that of control group (P<0.05). ③ There is no statistically significant difference in TC， TG， Ca²⁺， P³⁺， PTH among the groups (P>0.05). ④ BUN in treatment group is decreased (P<0.05) whose change is larger than that of control group (P<0.05). There is no statistically significant difference in Scr，KT/V，Ccr among the groups (P>0.05). CONCLUSION Yunpiqiangsheng Fang can help improve PD patients' QOL， which plays an important role in increasing appetite， enhancing digestion and absorption， regulating overall function of organs， thereby improving patients' nutrition.
- Yunpiqiangsheng Fang /
- peritoneal dialysis /
- quality of life /
- clinical research

HTML全文

参考文献(15)

[1]	《维持性腹膜透析》专家协作组.维持性腹膜透析共识[J]．中华肾脏病杂志，2006， 8（22）：513-516．
[2]	Experts on Maintenance Peritoneal Dialysis. Study on maintenance peritoneal dialysis[J]. Chin J Nephrol，2006，8(22):513-516.
[3]	Kalantar-Zadeh K， Kleiner M， Dunne E， et al. A modified quantitative subjective global assessment of nutrition for dialysis patients[J]. Nephrol Dial Transplant， 1999，14(7):1732-1738.
[4]	Hays RD， Kallich JD， Mapes DL， et al. Kidney disease quality of life short form (KDQOL-SF^TM)， Version 1.3: A manual for use and scoring[J]. Santa Monica CA:RAND Corporation，1997:110.
[5]	张虹，朱起之，王寅．中药养营汤与人类重组生长激素对腹膜透析患者并发营养不良的改善作用[J]．中国中西医结合肾病杂志，2006， 7（6）：353-355．
[6]	Zhang H，Zhu QZ， Wang Y. Effect of Chinese medicine and human recombinant reowth hormone on patients of maintenance peritoneal dialysis with malnutrition[J].Chin J Integr Tradit West Nephr， 2006，7(6):353-355.
[7]	Akdag I， Yilmaz Y， Kahvecioglu S， et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study[J]. Nephron Clin Pract， 2008， 108(2):99-105.
[8]	郑智化，马祖，郝元涛，等．持续性非卧床腹膜透析患者生存质量影响因素研究[J]．中华肾病杂志，2005， 21（5）：290-294．
[9]	Zheng ZH， Ma Z， Hao YT， et al. Research on factors for quality of life of patients receiving continuous ambulatory peritoneal dialysis[J].Chin J Nephrol，2005，21(5):290-294.
[10]	Szeto CC， Wong TY， Chow KM， et al. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death[J]. Nephrol Dial Transplant， 2003， 18(5): 977-982.
[11]	杜义斌，陶尚成．持续性不卧床腹膜透析并发症消化功能紊乱的中医治疗观察[J]．中国中西医结合肾病杂志，2002， 3（1）：32-33．
[12]	Du YB， Tao SC. Chinese medicine treating disorders of digestion in patients undergoing continuous ambulatory peritoneal dialysis[J]. Chin J Integr Tradit West Nephr， 2002， 3(1):32-33.
[13]	金惠敏．当前腹膜透析营养不良的现状和挑战[J]．中国血液净化，2008，7（8）：430-432．
[14]	Jin HM. Present situation and challenges of malnutrition in patients with maintenance peritoneal dialysis[J]. Chin J Blood Purification， 2008，7(8):430-432.
[15]	Korevaar JC， Merkus MP， Jansen MA， et al. Vali-dation of the KDQOL-SFTM:A dialysis-targeted healthmeasure[J]. Qual Life Res， 2002，11(5):437-447.